Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidoglycan D,D-transpeptidase MrdA—commonly known as penicillin-binding protein 2 (PBP2)—is an essential membrane-bound enzyme found in Gram-negative bacteria such as *Escherichia coli*. It catalyzes the cross-linking step during peptidoglycan biosynthesis by forming peptide bonds between adjacent glycan strands, which provides mechanical strength and rigidity to the bacterial cell wall. This activity is crucial for maintaining rod-shaped morphology and proper cellular growth. The inhibition of MrdA/PBP2 by β-lactam antibiotics disrupts peptidoglycan assembly, leading to loss of structural integrity and ultimately bacterial lysis. Due to its central role in cell wall synthesis and its absence from eukaryotic cells, it serves as a major therapeutic target for antibacterial agents targeting infectious diseases caused by susceptible bacteria.
Inhibition of peptidoglycan cross-linking by covalent binding to the active serine residue within the transpeptidase domain. Disruption of bacterial cell wall synthesis resulting in bacteriolysis or loss of viability.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidoglycan D,D-transpeptidase MrdA (PBP2).